I/O player iTeos lines up a $75M round as it preps for human studies, plans a leap to US hub
The Belgian biotech iTeos is finding out just how generous investors can be when it comes to backing a new drug that might play a key assist with the first-generation of immuno-oncology drugs on the market. The group has hauled in a $75 million round designed to get its lead drug — an adenosine A2A antagonist — into the clinic later this year.
The money will also fund a move into Cambridge, MA as the biotech builds out its top team in the US in preparation for an IPO at some point.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.